# biospace (news sources) — RSS Amplifier Recent posts from the 1 feeds in the RSS Amplifier directory that cover biospace. Page: Feed: --- ## [Lawmakers urge FDA to enact new China policies after 3 gene therapy deaths](https://www.biospace.com/policy/lawmakers-urge-fda-to-enact-new-china-policies-after-3-gene-therapy-deaths) _2026-08-21 · Gabrielle Masson · All News_ Three fatalities occurring recently in China clinical trials have spurred two members of U.S. Congress to urge the FDA to enact new policies designed to protect American patients. ## [Werewolf and Ambros to tie the knot in $150M rare disease deal](https://www.biospace.com/deals/werewolf-and-ambros-to-tie-the-knot-in-150m-rare-disease-deal) _2026-08-21 · Michael Gibney · All News_ The merger, which would create a new company bearing Ambros’ name, will help support development of Ambros' non-opioid painkiller for patients with debilitating limb injuries. ## [Novo Nordisk starts trialing lower maintenance doses of oral Wegovy](https://www.biospace.com/drug-development/novo-nordisk-starts-trialing-lower-maintenance-doses-of-oral-wegovy) _2026-08-21 · Nick Paul Taylor · All News_ The Phase 3 study is evaluating two doses of Novo’s Wegovy pill in people with obesity or overweight in combination with a reduced-calorie diet and increased physical activity. ## [Roche pours $750M into Oregon manufacturing plant as obesity push expands](https://www.biospace.com/drug-delivery/roche-pours-750m-into-oregon-manufacturing-plant-as-obesity-push-expands) _2026-08-20 · Gabrielle Masson · All News_ After committing $2 billion to a new North Carolina facility to boost capacity for its next-gen obesity candidates, Roche's Genentech is putting down more cash to expand a device fill-finish site in Oregon. ## [Scribe’s early-stage IPO standout defies biotech’s derisking trend](https://www.biospace.com/business/scribes-early-stage-ipo-standout-defies-biotechs-derisking-trend) _2026-08-20 · Gabrielle Masson · All News_ Scribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering therapies while sidestepping the irreversibility of gene editing. ## [Regeneron wins FDA approval to challenge Ipsen for rare bone disease market](https://www.biospace.com/fda/regeneron-wins-fda-approval-to-challenge-ipsen-for-rare-bone-disease-market) _2026-08-20 · Nick Paul Taylor · All News_ Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos. ## [Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision](https://www.biospace.com/fda/ultragenyx-bags-first-gene-therapy-approval-as-previously-rejected-sanfilippo-asset-awaits-decision) _2026-08-20 · Nick Paul Taylor · All News_ The accelerated greenlight for Ultragenyx’s gene therapy for glycogen storage disease has raised analyst expectations for approval of UX111, which the FDA rejected last summer and is currently reviewing for a second time. A decision is expected by mid-September. ## [Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future](https://www.biospace.com/business/mercks-moderna-partnered-vaccine-success-clears-view-of-post-keytruda-future) _2026-08-20 · Annalee Armstrong · All News_ Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise. ## [Rewriting the rules of CMV prevention](https://www.biospace.com/drug-development/rewriting-the-rules-of-cmv-prevention) _2026-08-20 · Jennifer C. Smith-Parker · All News_ In this episode of Denatured, you’ll hear from Ian McGowan, Chief Medical Officer at Synklino and James Hunter, associate professor of transplantation at Oxford University. We explore transplantation and antiviral innovation and why CMV remains one of the most persistent and consequential challenges facing transplant patients today. ## [7 biopharma M&A deals where layoffs followed](https://www.biospace.com/job-trends/7-biopharma-m-a-deals-where-layoffs-followed) _2026-08-20 · Angela Gabriel · All News_ Workforce cuts this year at seven companies involved in recent mergers and acquisitions will cost over 1,300 employees their jobs. Affected businesses include Arcellx and Tourmaline Bio, acquired by Gilead Sciences and Novartis, respectively. ## [Ask the crowd: AI or not (Sponsored)](https://crawlproof.com/a/g4XkGE9PvYjZ) _2026-08-20 · **Sponsored**_ Get a transparent verdict from verified humans via web, RSS, or API. ## [Out of sight, out of work? What’s driving remote job cuts](https://www.biospace.com/job-trends/out-of-sight-out-of-work-whats-driving-remote-job-cuts) _2026-08-20 · Angela Gabriel · All News_ Biopharma professionals sometimes find themselves out of jobs when employers want to bring staff back into the office, as recently seen at biotech EMD Serono and Exelixis. ## [Why pediatric rare oncology outperforms in a volatile biotech market](https://www.biospace.com/drug-development/opinion-why-pediatric-rare-oncology-outperforms-in-a-volatile-biotech-market) _2026-08-20 · Paul Romness · All News_ Real progress happens where unmet medical need is greatest and patient impact can be clearly measured. Pediatric rare cancers exemplify these criteria and have therefore generated continued investment, even in a capital-constrained environment. ## [Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: Analysts](https://www.biospace.com/fda/trumps-fda-pick-overton-good-for-psychedelics-new-pain-meds-but-bad-for-vaccines-analysts) _2026-08-19 · Heather McKenzie · All News_ If confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA commissioner—is expected to be a boon for developers of psychedelic therapeutics and non-opioid pain drugs, but could tow the party line on vaccines.